Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antigens, CD20"" wg kryterium: Temat


Tytuł :
Noninvasive Evaluation of CD20 Expression Using Cu-Labeled F(ab') 2 Fragments of Obinutuzumab in Lymphoma.
Autorzy :
Kang L; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin.
Li C; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Rosenkrans ZT; Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin.
Engle JW; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin.
Wang R; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Jiang D; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin.; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and.
Xu X; Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, China.
Cai W; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin .; Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Mar; Vol. 62 (3), pp. 372-378. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Antibodies, Monoclonal, Humanized/*immunology
Antigens, CD20/*metabolism
Copper Radioisotopes/*chemistry
Immunoglobulin Fab Fragments/*chemistry
Lymphoma/*metabolism
Animals ; Antigens, CD20/immunology ; Cell Line, Tumor ; Cell Transformation, Neoplastic ; Humans ; Isotope Labeling ; Lymphoma/diagnostic imaging ; Male ; Mice
Czasopismo naukowe
Tytuł :
CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features.
Autorzy :
Huang Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Chen S; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Wei R; Department of Pathology, Second Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Guo X; Department of Pathology, Hospital Affiliated to Qinghai University, Xining, Qinghai, People's Republic of China.
Yang X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Cao Q; Department of Pathology, The first affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Yang Y; Department of Pathology, Chinese Traditional Medical Hospital of Guangdong Province, Guangzhou, Guangdong, 510120, People's Republic of China.
Yun J; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China. .; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Dec; Vol. 477 (6), pp. 873-883. Date of Electronic Publication: 2020 Apr 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antigens, CD20/*immunology
Lymphoma, Extranodal NK-T-Cell/*immunology
Lymphoma, Extranodal NK-T-Cell/*pathology
Adult ; Aged ; Aged, 80 and over ; Antigens, CD20/metabolism ; Female ; Humans ; Male ; Middle Aged ; Prognosis
Czasopismo naukowe
Tytuł :
CD3-CD20-positive nodal lymphoma with cross-lineage rearrangement in a dog.
Autorzy :
Nicoletti A; School of Agriculture and Veterinary Medicine, University of Turin, Grugliasco, Turin, Italy.
Aresu L; School of Agriculture and Veterinary Medicine, University of Turin, Grugliasco, Turin, Italy.
Marino M; Laboratorio La Vallonea, Passirana di Rho, Milano, Italy.
Massaro M; Laboratorio La Vallonea, Passirana di Rho, Milano, Italy.
Martignani E; School of Agriculture and Veterinary Medicine, University of Turin, Grugliasco, Turin, Italy.
Caporali E; Clinica Veterinaria San Rocco, Foiana della Chiana, Arezzo, Italy.
Capuccini S; Clinica Veterinaria San Rocco, Foiana della Chiana, Arezzo, Italy.
Bonfanti U; Laboratorio La Vallonea, Passirana di Rho, Milano, Italy.
Gola C; School of Agriculture and Veterinary Medicine, University of Turin, Grugliasco, Turin, Italy.
Pokaż więcej
Źródło :
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc [J Vet Diagn Invest] 2020 Nov; Vol. 32 (6), pp. 964-967. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Gene Rearrangement*
Antigens, CD20/*genetics
CD3 Complex/*genetics
Dog Diseases/*diagnosis
Dog Diseases/*genetics
Lymphoma, Large B-Cell, Diffuse/*veterinary
Animals ; Antigens, CD20/metabolism ; CD3 Complex/metabolism ; Dog Diseases/physiopathology ; Dogs ; Fluorescent Antibody Technique/veterinary ; Immunohistochemistry ; Lymph Nodes/pathology ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/physiopathology ; Male
Czasopismo naukowe
Tytuł :
In-depth B cell immunophenotyping to monitor response to anti-CD20 therapy in CNS autoimmunity.
Autorzy :
Su E; Stanford University School of Medicine, Neurology 300 Pasteur Dr. Stanford, CA, USA 94305. Electronic address: .
Wetzel NS; Stanford University, Neurology and Neurological Sciences, USA; University of Zurich, Faculty of Medicine, Pestalozzistrasse 3/5, 8091 Zurich, CH. Electronic address: .
Oak J; Stanford University, Department of Pathology, 300 Pasteur Dr, Stanford, CA, USA 94305. Electronic address: .
Kipp L; Stanford University School of Medicine, Neurology 300 Pasteur Dr. Stanford, CA, USA 94305. Electronic address: .
Han MH; Stanford University, Neurology and Neurological Sciences, USA. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Nov; Vol. 46, pp. 102594. Date of Electronic Publication: 2020 Oct 24.
Typ publikacji :
Letter
MeSH Terms :
Antigens, CD20*
Autoimmunity*
B-Lymphocytes ; Immunophenotyping
Opinia redakcyjna
Tytuł :
B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis.
Autorzy :
Nissimov N; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.
Hajiyeva Z; Department of Neurology, University Medical Center, 37075 Göttingen, Germany.
Torke S; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.
Grondey K; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.
Brück W; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.
Häusser-Kinzel S; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.
Weber MS; Institute of Neuropathology, University Medical Center, 37075 Göttingen, Germany; .; Department of Neurology, University Medical Center, 37075 Göttingen, Germany.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Oct 13; Vol. 117 (41), pp. 25690-25699. Date of Electronic Publication: 2020 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies/*administration & dosage
Antigens, CD20/*immunology
B-Lymphocytes/*immunology
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Multiple Sclerosis, Relapsing-Remitting/*immunology
Adult ; Antigens, CD/genetics ; Antigens, CD/immunology ; Antigens, CD20/genetics ; Antigens, Differentiation, T-Lymphocyte/genetics ; Antigens, Differentiation, T-Lymphocyte/immunology ; B-Lymphocytes/cytology ; B7-2 Antigen/genetics ; B7-2 Antigen/immunology ; Female ; Humans ; Immunologic Memory ; Lectins, C-Type/genetics ; Lectins, C-Type/immunology ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/genetics ; T-Lymphocytes/cytology ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
Autorzy :
Schäfer D; Translational Molecular Imaging, Institute for Diagnostic and Interventional Radiology & Clinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Henze J; Translational Molecular Imaging, Institute for Diagnostic and Interventional Radiology & Clinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Pfeifer R; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Schleicher A; Faculty of Chemistry and Biosciences, Karlsruher Institute of Technology, Karlsruhe, Germany.
Brauner J; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Mockel-Tenbrinck N; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Barth C; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Gudert D; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Al Rawashdeh W; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Johnston ICD; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Hardt O; R&D Reagents, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Aug 07; Vol. 11, pp. 1704. Date of Electronic Publication: 2020 Aug 07 (Print Publication: 2020).
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Immunotherapy, Adoptive*
Antigens, CD20/*immunology
Carcinoma, Pancreatic Ductal/*therapy
Lymphoma/*therapy
Myelin-Associated Glycoprotein/*genetics
Pancreatic Neoplasms/*therapy
Receptors, Chimeric Antigen/*immunology
T-Lymphocytes/*transplantation
Animals ; Antigens, CD20/genetics ; Antigens, CD20/metabolism ; Carcinoma, Pancreatic Ductal/immunology ; Carcinoma, Pancreatic Ductal/metabolism ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor ; Cytokines/immunology ; Cytokines/metabolism ; Disease Models, Animal ; HEK293 Cells ; Humans ; Lymphoma/immunology ; Lymphoma/metabolism ; Lymphoma/pathology ; Mice, Inbred NOD ; Mice, SCID ; Myelin-Associated Glycoprotein/immunology ; Myelin-Associated Glycoprotein/metabolism ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Phenotype ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tumor Burden ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Autorzy :
Breakell T; Institute of Anatomy and Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Tacke S; Institute of Anatomy and Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Schropp V; Institute of Anatomy and Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180 Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.; UK Dementia Research Institute at UCL, London WC1E 6BT, UK.
Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180 Mölndal, Sweden.
Urich E; Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center, 4070 Basel, Switzerland.
Kuerten S; Institute of Anatomy and Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 18; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antigens, CD20/*immunology
Antineoplastic Agents, Immunological/*administration & dosage
B-Lymphocytes/*immunology
Encephalomyelitis, Autoimmune, Experimental/*drug therapy
Multiple Sclerosis, Chronic Progressive/*drug therapy
Spinal Cord/*drug effects
Animals ; Antibodies, Monoclonal/administration & dosage ; Antigens, CD20/metabolism ; Axons/drug effects ; Axons/immunology ; Axons/pathology ; B-Lymphocytes/pathology ; Chronic Disease/drug therapy ; Disease Models, Animal ; Encephalomyelitis, Autoimmune, Experimental/immunology ; Encephalomyelitis, Autoimmune, Experimental/pathology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microscopy, Electron ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/immunology ; Multiple Sclerosis/pathology ; Multiple Sclerosis, Chronic Progressive/immunology ; Multiple Sclerosis, Chronic Progressive/pathology ; Myelin Basic Protein/immunology ; Myelin Proteolipid Protein/immunology ; Neurofilament Proteins/blood ; Recombinant Fusion Proteins/immunology ; Spinal Cord/immunology ; Spinal Cord/pathology ; Spinal Cord/ultrastructure
Czasopismo naukowe
Tytuł :
Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Autorzy :
Maeshima AM; Department of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. .
Taniguchi H; Department of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Fujino T; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Saito Y; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Ito Y; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Hatta S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Yuda S; Department of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Makita S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Fukuhara S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Munakata W; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Suzuki T; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Maruyama D; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 2141-2148. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, CD20/*immunology
Antineoplastic Agents, Immunological/*therapeutic use
Lymphoma, B-Cell/*drug therapy
Lymphoma, B-Cell/*immunology
Rituximab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antigens, CD20/chemistry ; Cohort Studies ; Female ; Humans ; Lymphoma, B-Cell/diagnosis ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Combination therapy with anti-CD20 mAb and IL-10 gene to reverse type 1 diabetes by attenuating pancreatitis and inhibiting apoptosis in NOD mice.
Autorzy :
Li C; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China.
Zhang L; Department of Pediatric Endocrinologic Diseases, the Affiliated Hospital of Qingdao University, Qingdao 266555, Shandong, China.
Qiao L; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China.
Hu S; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China.
Ge J; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China.
Hu C; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China.
Li T; Department of Pediatric Endocrinologic and Genetic and Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao 266000, Shandong, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Sep 01; Vol. 256, pp. 117985. Date of Electronic Publication: 2020 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antigens, CD20/*administration & dosage
Apoptosis/*drug effects
Diabetes Mellitus, Type 1/*drug therapy
Interleukin-10/*administration & dosage
Pancreatitis/*drug therapy
Adenoviridae/genetics ; Animals ; Antibodies, Monoclonal/genetics ; Antigens, CD20/genetics ; Apoptosis/genetics ; Diabetes Mellitus, Type 1/genetics ; Diabetes Mellitus, Type 1/pathology ; Drug Therapy, Combination ; Female ; Interleukin-10/genetics ; Male ; Mice ; Mice, Inbred NOD ; Pancreatitis/genetics ; Pancreatitis/pathology
Czasopismo naukowe
Tytuł :
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Autorzy :
Houot R; Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: .
Levy R; Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Cartron G; Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.
Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 4-6. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, CD20*
Coronavirus Infections/*prevention & control
Immunologic Factors/*adverse effects
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Rituximab/*adverse effects
Viral Vaccines/*therapeutic use
Antibodies, Monoclonal, Humanized/adverse effects ; Betacoronavirus ; COVID-19 ; COVID-19 Vaccines ; Drug Interactions ; Humans ; SARS-CoV-2 ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Binding mechanisms of therapeutic antibodies to human CD20.
Autorzy :
Kumar A; Membrane Protein Mechanisms Unit, Institut Pasteur, 75015 Paris, France.; Membrane Protein Mechanisms Group, European Institute of Chemistry and Biology, University of Bordeaux, 33607 Pessac, France.; CNRS UMR 5234 Fundamental Microbiology and Pathogenicity, Bordeaux, France.
Planchais C; Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.; INSERM U1222, Paris, France.
Fronzes R; CNRS UMR 5234 Fundamental Microbiology and Pathogenicity, Bordeaux, France.; Structure and Function of Bacterial Nanomachines Group, European Institute of Chemistry and Biology, University of Bordeaux, 33607 Pessac, France.
Mouquet H; Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.; INSERM U1222, Paris, France.
Reyes N; Membrane Protein Mechanisms Unit, Institut Pasteur, 75015 Paris, France. .; Membrane Protein Mechanisms Group, European Institute of Chemistry and Biology, University of Bordeaux, 33607 Pessac, France.; CNRS UMR 5234 Fundamental Microbiology and Pathogenicity, Bordeaux, France.
Pokaż więcej
Źródło :
Science (New York, N.Y.) [Science] 2020 Aug 14; Vol. 369 (6505), pp. 793-799.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*
Antibodies, Monoclonal, Humanized/*chemistry
Antigen-Antibody Complex/*chemistry
Antigens, CD20/*chemistry
Antineoplastic Agents/*chemistry
Lymphoma, B-Cell/*therapy
Rituximab/*chemistry
Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigen-Antibody Complex/immunology ; Antigens, CD20/immunology ; Antineoplastic Agents/immunology ; B-Lymphocytes/immunology ; Complement Activation ; Cryoelectron Microscopy ; Humans ; Immunoglobulin Fab Fragments/chemistry ; Immunoglobulin Fab Fragments/immunology ; Protein Binding ; Protein Conformation ; Rituximab/immunology ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł :
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Autorzy :
Sang W; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shi M; Cancer Institute, Xuzhou Medical University, Xuzhou, China.
Yang J; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Cao J; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China.
Xu L; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China.
Yan D; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yao M; Department of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Liu H; Department of Pathology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Li W; Department of Radiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang B; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Sun K; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Song X; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Sun C; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiao J; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qin Y; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Sang T; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China.
Ma Y; Department of Pathology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wu M; Department of Pathology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Gao X; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Cheng H; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yan Z; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Li D; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Sun H; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhu F; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wang Y; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zeng L; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China.
Li Z; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zheng J; Cancer Institute, Xuzhou Medical University, Xuzhou, China.
Xu K; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2020 Aug; Vol. 9 (16), pp. 5827-5838. Date of Electronic Publication: 2020 Jul 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD19*
Antigens, CD20*
Immunotherapy, Adoptive/*methods
Lymphoma, Large B-Cell, Diffuse/*therapy
Receptors, Chimeric Antigen/*therapeutic use
T-Lymphocytes/*transplantation
Adult ; Aged ; Anemia/etiology ; Antineoplastic Agents/therapeutic use ; B-Lymphocytes ; CD4-CD8 Ratio ; Confidence Intervals ; Cyclophosphamide/therapeutic use ; Cytokine Release Syndrome/etiology ; Female ; Glycolysis ; Humans ; Ifosfamide/therapeutic use ; Immunotherapy, Adoptive/adverse effects ; Lymphoma, Large B-Cell, Diffuse/blood ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Neutropenia/etiology ; Progression-Free Survival ; Recurrence ; Thrombocytopenia/etiology ; Time Factors ; Transplantation Conditioning/methods ; Treatment Outcome ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20 B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study.
Autorzy :
Jiang B; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Ke X; Hematology Department, Peking University Third Hospital, Beijing, China.
Zhang Q; Oncology Department, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, China.
Xu W; Hematology Department, Jiangsu Province Hospital, Nanjing, China.
Su H; Department of Lymphoma/Head and Neck Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Huang J; Hematology Department, West China Hospital Sichuan University, Chengdu, China.
Zhang M; Oncology Department, The First Affiliated Hospital of Zhengzhou Medical University, Zhengzhou, China.
Wang H; Oncology Department, Tianjin Union Medical Center Nankai University Affiliated Hospital, Tianjin, China.
Jin C; Forth Medical Department, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
Liu L; Hematology Department, Tangdu Hospital, The Medical University of Air Forces, Xi'an, China.
Cai Z; Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Zhao X; Hematology Department, Xiangya Hospital Central South University, Changsha, China.
Zhou J; Hematology Department, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
Zhang X; Hematology Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Liu J; Hematology Department, The Third Xiangya Hospital of Central South University, Changsha, China.
Zhou H; Innovent Biologics, Inc., Suzhou, China.
Yu J; Innovent Biologics, Inc., Suzhou, China.
Sun X; Innovent Biologics, Inc., Suzhou, China.
Qi J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Jul 15; Vol. 10 (1), pp. 11676. Date of Electronic Publication: 2020 Jul 15.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacokinetics
Antigens, CD20/*immunology
Antineoplastic Agents, Immunological/*pharmacokinetics
B-Lymphocytes/*drug effects
Lymphoma, B-Cell/*drug therapy
Rituximab/*pharmacokinetics
Adult ; Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/pharmacology ; Antigens, CD20/genetics ; Antineoplastic Agents, Immunological/blood ; Antineoplastic Agents, Immunological/pharmacology ; Area Under Curve ; B-Lymphocytes/immunology ; B-Lymphocytes/pathology ; Biological Availability ; Biosimilar Pharmaceuticals ; Double-Blind Method ; Female ; Gene Expression ; Humans ; Injections, Intravenous ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/immunology ; Lymphoma, B-Cell/pathology ; Male ; Middle Aged ; Patient Safety ; Rituximab/blood ; Rituximab/pharmacology
Czasopismo naukowe
Tytuł :
[Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
Autorzy :
Zhang DD; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Hu PZ; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Li P; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Jiang GZ; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yin YH; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Wang GN; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Zhao WG; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Zhang YP; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Li WC; Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Pokaż więcej
Źródło :
Zhonghua bing li xue za zhi = Chinese journal of pathology [Zhonghua Bing Li Xue Za Zhi] 2021 Jun 08; Vol. 50 (6), pp. 592-597.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*
Lymphoma, B-Cell*
Waldenstrom Macroglobulinemia*/genetics
Adult ; Aged ; Aged, 80 and over ; Antigens, CD20 ; Female ; Humans ; Immunophenotyping ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
Autorzy :
Kuroda Y; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.; Department of Hematology, National Hospital Organization Hiroshimanishi Medical Center, 4-1-1 Kuba, Otake, Hiroshima, 739-0696, Japan.
Yashima-Abo A; Department of Pathology, School of Medicine, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cho, Shiwa, Iwate, 028-3694, Japan.
Koyama D; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Kikuchi J; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Mori S; Medical Education Center, Saitama Medical University, 38 Morohongo, Saitama, 350-0495, Japan.
Ito S; Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cho, Shiwa, Iwate, 028-3694, Japan.
Furukawa Y; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 May; Vol. 35 (5), pp. 1506-1510. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD20/*metabolism
Antineoplastic Agents, Immunological/*therapeutic use
Bone Marrow/*metabolism
Drug Resistance, Neoplasm/*drug effects
Lymphoma, Mantle-Cell/*drug therapy
Lymphoma, Mantle-Cell/*metabolism
Rituximab/*therapeutic use
Stromal Cells/*metabolism
Humans ; Mesenchymal Stem Cells/metabolism
Raport
Tytuł :
[Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma involving the small intestine: a case report].
Autorzy :
Cao X; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Cai YF; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Lin ZH; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Qian J; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Feng J; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Sun CF; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Jiang SH; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
You XF; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Liu H; Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Pokaż więcej
Źródło :
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2021 Apr 14; Vol. 42 (4), pp. 346.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Lymphoma, Large B-Cell, Diffuse*
Lymphoma, T-Cell, Peripheral*
Antigens, CD20 ; Humans ; Intestine, Small
Czasopismo naukowe
Tytuł :
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
Autorzy :
Cotchett KR; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI; Versiti Blood Research Institute, Milwaukee, WI.
Dittel BN; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI; Versiti Blood Research Institute, Milwaukee, WI.
Obeidat AZ; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Apr; Vol. 49, pp. 102787. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Sclerosis*/drug therapy
Pharmaceutical Preparations*
Antigens, CD20 ; B-Lymphocytes ; Humans ; Rituximab
Czasopismo naukowe
Tytuł :
STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane.
Autorzy :
Heo W; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Jin N; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Park MS; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Kim HY; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Yoon SM; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea.
Lee J; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea.
Kim JY; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło :
Clinical and experimental immunology [Clin Exp Immunol] 2020 Jun; Vol. 200 (3), pp. 260-271. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Knockdown Techniques*
Antibodies, Monoclonal, Humanized/*immunology
Antigens, CD20/*immunology
Cell Membrane/*immunology
Neoplasm Proteins/*immunology
Stromal Interaction Molecule 1/*immunology
Animals ; Antigens, CD20/genetics ; CHO Cells ; Cell Membrane/genetics ; Cricetulus ; Humans ; Neoplasm Proteins/genetics ; Octoxynol/chemistry ; Solubility ; Stromal Interaction Molecule 1/genetics
Czasopismo naukowe
Tytuł :
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.
Autorzy :
Pavlasova G; Central European Institute of Technology, Masaryk University, Brno.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Mraz M; Central European Institute of Technology, Masaryk University, Brno .; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Jun; Vol. 105 (6), pp. 1494-1506.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antigens, CD20*
Leukemia, Lymphocytic, Chronic, B-Cell*
Antibodies, Monoclonal ; B-Lymphocytes ; Humans ; Pyrimidines ; Rituximab
Czasopismo naukowe
Tytuł :
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.
Autorzy :
Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Jun; Vol. 41, pp. 102135. Date of Electronic Publication: 2020 Apr 18.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antigens, CD20*
Immunosuppression*
Antibodies, Monoclonal, Humanized ; Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies